Urology Times

In an interview at #GU25, Gopa Iyer, MD, shared key findings from the FORAGER-1 trial, which assessed LOXO-435, an isoform-selective FGFR3 inhibitor, in patients with metastatic urothelial carcinoma. According to Iyer, LOXO-435 may limit off-target toxicities compared with erdafitinib, which is a pan FGFR1-4 inhibitor. 📹 Watch here: https://lnkd.in/ew_KAZZR Memorial Sloan Kettering Cancer Center | #BLCSM

The FDA has accepted and granted priority review to a biologics license application for 89Zr-DFO-girentuximab for PET imaging of clear cell renal cell carcinoma (#ccRCC). The application is supported by data from the phase 3 #ZIRCON trial, in which the agent demonstrated high specificity and sensitivity in detecting ccRCC in patients with an indeterminate renal mass. Read more: https://lnkd.in/eKHiem3W #KCSM

In an interview with Urology Times, Dean Elterman, MD, MSc, FRCSC, discussed the concept of “first-line interventional therapy,” or #FIT, for the management of #BPH. Listen to his insights here: https://lnkd.in/eNPsjSS9

Michael Schweizer, MD, of Fred Hutch Cancer Center recently sat down with Urology Times to discuss findings from a phase 2 trial of mevrometostat plus enzalutamide vs enzalutamide alone in patients with mCRPC. The data, shared at #GU25, showed an improvement in rPFS with mevrometostat plus enzalutamide, supporting the initiation of phase 3 trials of the combination in prostate cancer. Learn more from Dr. Schweizer here: https://lnkd.in/eVYrWW73

#ICYMI: Last week the FDA authorized an Expanded Access Program that will provide an alternative source of BCG to patients across the US. The program, initiated through a partnership between ImmunityBio, Inc. and the Serum Institute of India Pvt. Ltd., is set to begin shipments of recombinant BCG immediately. The hope is that this program will help to address the ongoing shortage of TICE BCG in the US. Read more: https://lnkd.in/gwZVrT-C

💪 Urologists Have a Role in Muscle Preservation for Patients on GLP-1 Medications At the 2024 AUA Annual Meeting, I presented a case during the Sexual Medicine Society of North America (SMSNA) section that highlights something I’m passionate about—helping men not just lose weight, but also preserve muscle and optimize their health. Here’s the case: A 47-year-old male—a former runner who had gained significant weight—came to see my twin sister, Michelle Pearlman, M.D., a gastroenterologist, for weight loss. He had all the usual symptoms we see in obesity and low testosterone: fatigue, sluggishness, and reduced libido. She started him on a GLP-1 agonist, and he started losing weight—great, right? Not so fast. GLP-1s don’t just lead to fat loss; they also often result in muscle loss. And this guy already had low skeletal muscle mass at baseline. When my sister checked his testosterone, it was in the high 200s—low, but not surprising. She sent him to me, I started testosterone therapy, and that’s when things changed. A year later, not only had he lost 44 pounds and 10 inches off his waist, but he had more muscle mass than when he started. That should be a headline! While pharmaceutical companies are scrambling to develop new drugs to preserve muscle in GLP-1 patients, what if we already have a solution? 👉 Testosterone replacement therapy. As urologists, we already know how to optimize testosterone. We have a place in weight management. For my patients on GLP-1s, my go-to therapies are: ✅ Oral testosterone (Kyzatrex by Marius Pharmaceuticals) ✅ Testosterone cypionate injections Choice depends on patient preference, risk tolerance, and goals. Let’s start talking about this more. Weight loss doesn’t have to mean muscle loss. And as urologists, we need to be at the table when it comes to managing men’s health in the era of GLP-1s. Always a pleasure interviewing with Urology Times https://lnkd.in/e9umPCCv #Urology #MensHealth #GLP1 #Testosterone #AUA2024 #ObesityMedicine #MusclePreservation

In an interview at #GU25, Kathryn Gessner, MD, PhD, of UNC School of Medicine discussed the mechanisms of immunotherapy failure in renal cell carcinoma. Watch the full video here: https://lnkd.in/e-rwTrGA #RCC #KCSM

Sunday Spotlight 🌟 : In this video, Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, gives an overview of the study “Impact of physicians’ awareness of prostate-specific antigen doubling time (PSADT) on treatment (Tx) decisions in high-risk (HR) biochemically recurrent (BCR) prostate cancer (PC),” which she presented at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California. For more 🔗 : https://lnkd.in/gzahwdnB

Ashish Kamat, MD, MBBS provides expert insights into the recent shifts and evolution in the bladder cancer treatment landscape and the critical role of shared decision-making and personalized care, in this sponsored article. Read more: bit.ly/4hopKRQ #Sponsored by Johnson & Johnson

Article of the Week: The first reporting of real-world data for nadofaragene firadenovec-vncg (Adstiladrin) indicate that the non–muscle invasive bladder cance treatment yields positive efficacy and safety outcomes, investigators reported at the 2025 American Society of Clinical Oncology (ASCO) Oncology Genitourinary Cancers Symposium in San Francisco, California. 🔗: https://lnkd.in/gEkK2mNy